[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_95":96},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","x86tg7y42acs7lctk5dhe2lhe","revision",2,"title","TELA Bio获FDA对Liora Monofilament Scaffold产品的510(k)许可","originalTitle","TELA Bio, Inc. (0001561921) (Filer)","summary","TELA Bio于2026年10月5日宣布，其Liora Monofilament Scaffold产品已获美国食品药品监督管理局（FDA）510(k)许可。公司通过8-K提交了相关新闻稿作为附件。","reason","source",{"_11":85,"_86":87,"_88":89,"_90":57,"_91":92,"_93":94},"links",{"_82":83,"_63":84},"publishedAt","2026-10-05T12:05:26.000Z","discoveredAt","2026-10-05T12:20:37.262Z","timelineAt","category","ai-products","tags",[81],"stockSymbols",[80],"score",51,"selected",false,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":40},"outline",[],"relatedStories",[75],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","fzAiny847zhc",{"_72":73,"_15":74},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","b6cabeea-7aa5-44a6-badd-dd7fd56314b1","TELA Bio获FDA 510(k)许可",{"_72":73,"_15":74},"zh","

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):\nOctober 5, 2026

TELA Bio, Inc.

(Exact name of registrant as specified in its\ncharter)

\n \n \n \n \n \n \n \n \n \n \n \n \n

Delaware		001-39130		45-5320061
(State or other jurisdiction of \nincorporation)		(Commission \nFile Number)		(I.R.S. Employer \nIdentification No.)

\n \n \n \n \n \n \n \n \n

1 Great Valley Parkway, Suite 24

Malvern, Pennsylvania

19355

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including\narea code: (484) 320-2930

Not Applicable

(Former name or former address, if changed since\nlast report.)

Check the appropriate box below if the Form 8-K filing is intended\nto simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of\nthe Act:

\n \n \n \n \n \n \n \n \n \n \n \n \n

Title of each class		Trading \nSymbol(s)		Name of each exchange on which \nregistered
Common Stock, par value $0.001 per share		TELA		Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth\ncompany as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities\nExchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant\nhas elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant\nto Section 13(a) of the Exchange Act. ¨

\n \n \n \n

Item 8.01

Other Events.

On October 5, 2026, TELA Bio, Inc. issued a press release announcing\nthat it has received U.S. Food and Drug Administration 510(k) clearance for its Liora Monofilament Scaffold product. A copy of this press\nrelease is filed as Exhibit 99.1 hereto and incorporated herein by reference.

\n \n \n \n

Item\n 9.01

Financial\n Statements and Exhibits.

\n \n \n \n

(d)\n Exhibits:

\n \n \n \n \n \n \n \n \n \n \n \n \n

Exhibit\n Number		Description
99.1		Press\n Release of TELA Bio, Inc., dated October 5, 2026.
104		Cover\n Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

	TELA BIO, INC.

	By:	/s/ Heather Getz
	Name:	Heather Getz
	Title:	Chief Executive Officer and Director

Date: October 5, 2026

","zhKind","complete","TELA","公司与财报","aihot","/items/x86tg7y42acs7lctk5dhe2lhe","https://www.sec.gov/Archives/edgar/data/1561921/000110465926113506/0001104659-26-113506-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1791417600&sig=18cddd50281c55e6","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1791417600&sig=6c66a0408e1695ad 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1791417600&sig=11363acd4f484981 96w","changelogVersion","2026-10-01T08:00"]